Larvol Delta - Additional-Phase-2-Data-of-ALS-Pharmas-Lead-Program-AP101-Further-Demonstrate-Clinically-Meaningful-Disease-Modification-and-Prolonged-Survival-in-ALS

AP-101 - AL-S Pharma

https://www.businesswire.com/news/home/20260318619840/en/Additional-Phase-2-Data-of-AL-S-Pharmas-Lead-Program-AP-101-Further-Demonstrate-Clinically-Meaningful-Disease-Modification-and-Prolonged-Survival-in-ALS

Mar 19, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next